GPC3 and hepatocellular carcinoma: Shu et al. (95) used Fuc-PON1 (the ratio of fucosylated PON1 to total serum PON1) to differentiate AFP-negative early HCC (n = 76) from AFP-negative LC (n = 76) and found that Fuc-PON1 had an AUROC of 0.78, sensitivity of 62.2%, specificity of 67.7%, and accuracy of 64.5%, while the concentration alterations of AFP-L3 and glypican-3 (GPC3) in ANHC patients were not remarkable, indicating that Fuc-PON1 is useful in the diagnosis of AFP-negative early HCC.